Therefore, the authors showed that PD-L1 expression in lymph node metastases represents the best therapeutic outcome predictor in non-resectable advanced melanoma, while its assessment on skin/subcutaneous metastases should not be considered for use in therapy decision making. This evidence concerns the gene CD274 and metastatic malignant neoplasm in the lymph nodes.